Myeloid Diseases News from Poster Sessions
Mutant IDH (mIDH) inhibitors, ivosidenib or enasidenib, with azacitidine (AZA) in patients with acute myeloid leukemia (AML). First Author: Courtney Denton Dinardo, The University of Texas MD Anderson Cancer Center, Houston, TX
Conclusions:mIDH inhibitor + AZA regimens were generally well tolerated in pts with ND-AML. Most AEs were grade 1-2 GI events and ENA-related indirect bilirubin elevations due to off-target UGT1A1 inhibition. Response rates are encouraging. Phase 1b enrollment completed in late 2017; updated data for all 23 IVO and 6 ENA pts will be presented, as well as longitudinal changes in mIDH variant allele frequencies. Enrollment continues in the phase 2 portion of this study (ENA + AZA) and the phase 3 AGILE study of IVO + AZA (NCT03173248). Clinical trial information: NCT02677922